TY  - JOUR
AU  - García-Jiménez, Rocío
AU  - Valero, Irene
AU  - Corrales-Gutiérrez, Isabel
AU  - Granell, Reyes
AU  - Borrero, Carlota
AU  - Sainz-Bueno, José Antonio
PY  - 2022
DO  - 10.3390/biomedicines10102579
SN  - 2227-9059
UR  - http://hdl.handle.net/10668/20847
T2  - Biomedicines
AB  - Currently, cell-free DNA (cfDNA) is offered as part of a contingent screening for patients with a first-trimester combined test (FCT) risk between 1/50 and 1/250. However, most aneuploidies are within the group of patients with a risk above 1/10. An...
LA  - en
KW  - aneuploidy
KW  - cell-free DNA
KW  - contingent screening
KW  - first-trimester combined testing
KW  - non-invasive prenatal testing
KW  - trisomy 13
KW  - trisomy 18
KW  - trisomy 21
TI  - Does a High-Risk (>1/50) Result for First-Trimester Combined Screening Always Entail Invasive Testing? Which Patients from This Group Might Benefit from cfDNA Testing?
TY  - research article
VL  - 10
ER  -